Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study
Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study
复制标题
DOI:
10.1111/j.1464-410x.2011.10883.x
复制
发表时间:
2012-09-01
影响因子:
4.5
通讯作者:
Stenzl, Arnulf
中科院分区:
文献类型:
--
作者:
Huber, Severine;Schwentner, Christian;Stenzl, Arnulf
OBJECTIVETo evaluate the value of nuclear matrix protein-22 (NMP22) in bladder cancer (BC) screening, and its effect on variables in a prospective study in a high-risk population.PATIENTS AND METHODSA total of 1772 chemical workers (mean age 62 years) exposed to carcinogenic aromatic amines were enrolled in the study.In all, 7091 screening check-ups in 1609 subjects were performed.Urine samples were collected for a quantitative NMP22 immunoassay, urine analysis and creatinine concentration assessment.Cystoscopy and subsequent transurethral resection were performed where there were suspicious findings.RESULTSHistopathological analysis found three papillary urothelial neoplasms of low malignant potential, five recurrent BCs and 13 primary BCs. Three tumours were at a muscle-invasive stage (pT2, pT3a or pT3b).We found higher NMP22 concentrations (> 10 U/mL) in 224 patients, which correctly predicted BC in six cases (sensitivity 97.29%, specificity 28.57%; negative predictive value 99.04%, positive predictive value 12.24%).Gross haematuria affected NMP22 results (odd ratio [OR] 3.49, 95% confidence interval [CI] 1.81-6.73). Infection also affected NMP22 results (OR 4.13, 95% CI 2.31-7.35).NMP22 was more frequently positive in urine with creatinine concentration > 2.5 g/L (OR 1.61, 95% CI 0.91-2.86).CONCLUSIONSNMP22 outcomes are affected by haematuria, infection and concentrated urine.NMP22 alone cannot be recommended for primary screening in a high-risk population nor as an alternative to cystoscopy during follow-up.A NMP22 test might be a useful adjunct to urine cytology.